Open Menu
HOME
COMPANY
About us
PORIB team
Mission-Values
SERVICES
Economic Evaluation
Pricing and Reimbursement
Market Access
Real-World Evidence
Scientific Communication
Healthcare Management
Advisory Boards
Biostatistics
Training
CUSTOMERS
Pharmaceutical Industry
Scientific Societies
Universities and Training Schools
Other Collaborations
PUBLICATIONS
Therapeutic Area
Project Type
Papers
Abstracts
Books
TRAINING
BROCHURES
Corporate Brochure
Health Outcomes Research Brochure
Economic Evaluation Brochure
Statistical Evidence Brochure
en
es
Pharmacoeconomics & Outcomes Research Iberia
CONTACT
|
PORIB FOUNDATION
|
HOME
COMPANY
About us
PORIB team
Mission-Values
SERVICES
Economic Evaluation
Pricing and Reimbursement
Market Access
Real-World Evidence
Scientific Communication
Healthcare Management
Advisory Boards
Biostatistics
Training
CUSTOMERS
Pharmaceutical Industry
Scientific Societies
Universities and Training Schools
Other Collaborations
PUBLICATIONS
Therapeutic Area
Project Type
Papers
Abstracts
Books
TRAINING
BROCHURES
Corporate Brochure
Health Outcomes Research Brochure
Economic Evaluation Brochure
Statistical Evidence Brochure
en
es
Home
>
TRAINING
>
Training 2013
>
Revisión de criterios de evaluación de fármacos oncológicos.
Revisión de criterios de evaluación de fármacos oncológicos.
/
06 May 2013
Training 2013
Revisión de criterios de evaluación de fármacos oncológicos
Mayo 2013. Zaragoza
Previous Post
Estudios sobre Farmacoeconomía en el tratamiento de la Leucemia Mieloide Crónica con inhibidores tirosin kinasa. Jornada de Actualización profundizando en la leucemia mieloide crónica
Next Post
Evaluación Económica de fármacos en Oncología: en la práctica
